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            H
ypoxia inducible factor (HIF)-1, which is a het-
erodimer composed of HIF-1  a   and HIF-1  b ,  is 
an important transcription factor for cellular adaptation 
to hypoxia.    1,2     In normoxic condition, HIF-1  a   protein 
is constantly degraded because of ubiquitination and 
subsequent proteasomal degradation    . The ubiquitina-
tion of HIF-1  a   is caused by hydroxylation of prolyl res-
idues by prolyl hydroxylase, which is an oxygen-sensitive 
enzyme. In hypoxic condition, HIF-1  a   is stabilized 
because of inactivation of prolyl hydroxylase. As 
a result, HIF-1  a   translocates into the nucleus and 
binds speciﬁ  c binding sites on promoters of oxygen-
regulated genes, such as vascular endothelial growth 
factor (VEGF)    3    and  erythropoietin.  4   
  Histone deacetylase (HDAC) is an enzyme that 
removes an acetyl group from lysine on a histone. 
Deacetylation of histone proteins results in unwind-
ing of the chromatin structure, resulting in transcrip-
tional inactivation. Eighteen HDAC molecules are 
known and they are divided into three groups, types I, 
II, and III. The HDAC enzymes also deacetylate non-
histone proteins such as glucocorticoid receptor    5      a n d  
    Background:       Hypoxia inducible factor (HIF)-1 plays an important role in cellular adaptation to 
hypoxia by activating oxygen-regulated genes such as vascular endothelial growth factor (VEGF) 
and erythropoietin. Sputum VEGF levels are reported to be decreased in COPD, despite hypoxia. 
Here we show that patients with COPD fail to induce HIF-1  a   and VEGF under hypoxic condition 
because of a reduction in histone deacetylase (HDAC) 7. 
    Methods:       Peripheral blood mononuclear cells (PBMCs) were obtained from patients with moderate 
to severe COPD (n   5   21), smokers without COPD (n   5   12), and nonsmokers (n   5   15). PBMCs were 
exposed to hypoxia (1% oxygen, 5% CO  2  , and 94% N  2  ) for 24 h, and HIF-1  a   and HDAC7 protein 
expression in nuclear extracts were determined by sodium dodecyl sulfate poly acrylamide gel 
electrophoresis (SDS-PAGE)/Western blotting. 
    Results:       HIF-1  a   was signiﬁ  cantly induced by hypoxia in each group when compared with the 
normoxic condition (12-fold induction in nonsmokers, 24-fold induction in smokers without 
COPD, fourfold induction in COPD), but induction of HIF-1  a   under hypoxia was signiﬁ  cantly 
lower in patients with COPD than in nonsmokers and smokers without COPD (  P    ,    .05 and   P    ,   .01, 
respectively). VEGF messenger RNA detected by quantitative real-time polymerase chain reaction 
was correlated with HIF-1  a   protein in nuclei (r   5   0.79,  P    ,   .05), and HDAC7 protein expression 
was correlated with HIF-1  a   protein in nuclei (r    5   0.46,   P    ,    .05). HDAC7 knockdown inhibited 
hypoxia-induced HIF-1  a   activity in U937 cells, and HIF-1  a   nuclear translocation and HIF-1  a   
binding to the VEGF promoter in A549 cells. 
    Conclusions:       HDAC7 reduction in COPD causes a defect of HIF-1  a   induction response to hyp-
oxia with impaired VEGF gene expression. This poor cellular adaptation might play a role in the 
pathogenesis of COPD.       CHEST 2012; 141(5):1233–1242     
    Abbreviations  : CSM    5    cigarette smoke-conditioned medium; HDAC  5    histone deacetylase; HIF    5   hypoxia  inducible 
factor; mRNA   5   messenger RNA; NF-  k  B  5   nuclear factor- k  B; OD   5   optical density; PBMC   5   peripheral blood mono-
nuclear cell; PCR   5   polymerase chain reaction; siRNA   5   short interference RNA; TSA   5   trichostatin A; VEGF   5   vascu-
lar endothelial growth factor 
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  Peripheral Blood Mononuclear Cell Isolation 
and Peripheral Lung Tissue Collection 
  Peripheral blood mononuclear cells (PBMCs) were isolated 
using ACCUSPIN System-Histopaque (Sigma-Aldrich) according 
to the manufacturer’s instructions. Isolated PBMCs were resus-
pended in RPMI-1640 medium (Invitrogen) containing 10% fetal 
bovine serum and 2 mM   l  -glutamine. Peripheral lung tis  sue was 
obtained using a tissue bank linked to an established patient 
registry (e-Table 1).  15  
  Sputum Processing and Oxidative Stress Marker Measurement 
  Induced sputum samples were solubilized with 0.005% dithio-
threitol    . The solution was centrifuged at 1,500 rpm for 10 min 
to obtain cell-free supernatants. Malondialdehyde, an oxidative 
stress marker in sputum supernatants, was measured with a com-
mercially available thiobarbituric acid reactive substances assay 
kit (Cayman) according to the manufacturer’s instructions. 
 Hypoxia  Treatment 
 The Modular Incubator Chamber (MIC-101; Billups-Rothenberg 
Inc), a tightly sealed chamber, was used to maintain hypoxic 
conditions. PBMCs were seeded in culture dishes with 0.5   3  10 6 /mL 
and placed in the chamber. The hypoxia gas (1% oxygen, 5% CO  2 , 
and 94% N  2  ) was ﬂ  owed into the chamber at 20 L/min for 5 min, 
followed by incubation for 1 h at 37°C. This procedure was repeated 
three times prior to overnight incubation in the sealed chamber at 
37°C. If necessary, U937 cells (American Type Culture Collection) 
were treated with trichostatin A (TSA) (type I and II HDAC inhib-
itor) (Sigma-Aldrich) and incubated for 12 h under hypoxia. 
  In some experiments, hypoxia treatment was performed with 
AnaeroPack-Anaero 5% (Mitsubishi Gas Chemical Company, Inc) 
according to the manufacturer’s instructions. This system main-
tains 0.1% oxygen and 5% CO  2   for 24 h. With this system, HIF-1  a  
nuclear translocation was observed (e-Fig 1) the same as with 
the Modular Incubator Chamber system. 
  Reverse Transcription and Real-Time 
Quantitative Polymerase Chain Reaction     
  Total RNA extraction and reverse transcription of total RNA 
was done using the RNeasy kit and the Omniscript RT kit (QIA-
GEN), respectively, according to the manufacturer’s instructions. 
The VEGF messenger RNA (mRNA) expression was determined 
by real-time quantitative polymerase chain reaction (PCR) on a 
Rotor-Gene 3000 (Corbett Research) with TaqMan universal 
master mix and TaqMan primer mix (Applied Biosystems). The 
PCR cycles were 95°C for 15 s for denaturing, and 60°C for 1 min 
for annealing and extension. Data analysis was performed using 
the Rotor-Gene software. The amount of transcripts in each 
sample was standardized with that of guanine nucleotide binding 
protein,   b   polypeptide 2-like 1 (GNB2L1). 
 Protein  Detection 
  Nuclear proteins were extracted using a Nuclear Extraction 
kit (Active Motif) according to the manufacturer’s instructions. 
The protein samples were loaded onto the gel (10% Novex Tris-
Glycine Gel [Invitrogen]) and electrophoresed at 150 V, 40 mA, 
7.0 W for 90 min. The protein samples in the gels were blotted 
onto nitrocellulose membrane using the iBlot Dry Blotting System 
and iBlot Gel Transfer Stacks (Invitrogen) according to the manu-
facturer’s instructions. HIF-1  a   protein and HDAC7 protein 
were detected with anti-HIF-1  a   antibody (BD Biosciences) 
and HDAC7 antibody (Sigma-Aldrich), respectively. 
nuclear factor-  k  B (NF-  k  B)  .  6,7     We reported previously 
that HDAC2 is decreased in COPD    8     and is involved 
in steroid insensitivity.    5,9   
  Hypoxic condition is seen in patients with severe 
and very severe COPD or during exacerbations.    10   
Hypoxic condition is also seen even in patients with 
moderate COPD after exercise.    11    However,  VEGF 
has been reported to decrease with increasing severity 
of COPD,    12,13     despite hypoxic condition, although 
many proin  ﬂ  ammatory cytokines and chemokines are 
reported to increase and correlate with the severity of 
COPD.  14     It is speculated that the decreased VEGF 
levels in COPD affect the pathogenesis of emphysema.    12    
The molecular mechanisms of the paradoxic VEGF 
reduction are unknown. 
  We hypothesized that the impaired HIF-1  a  
response to hypoxia in patients with COPD is caused 
by impaired HIF-1  a   nuclear translocation due to 
reduction of HDAC7. The aim of this study was to 
investigate HIF-1  a  , HDAC7, and VEGF expression 
in clinical samples and to explore the relationship 
of the molecules using molecular biology methods. 
Here, we show that a poor HIF-1  a   response to hyp-
oxia is one of the features of patients with COPD and is 
caused by a reduction in HDAC7 protein expression. 
  Materials and Methods 
 Patient  Recruitment 
  Patients and healthy control subjects were recruited from the 
outpatient department of the Royal Brompton Hospital, local 
general practice, and the National Heart and Lung Institute. 
Patients with COPD were given a diagnosis using the criteria of 
the Global Initiative for Obstructive Lung Disease (GOLD).    10   
Patients with COPD who had had an exacerbation during the 
2 months prior to the visit were excluded. This study was reviewed 
and approved by the Hounslow and Hillingdon Research Ethics 
  Manuscript received June 19, 2011; revision accepted November 16, 
2011. 
  Afﬁ  liations    :   From the Airway Disease Section (Drs To, Yamamura, 
Akashi, Charron, Barnes, and Ito), National Heart and Lung 
Institute, Imperial College, London, England; and the Department 
of Laboratory Medicine (Drs To and Haruki), Dokkyo Medical 
University Koshigaya Hospital, Koshigaya-City, Saitama, Japan. 
  Funding    /Support:   Financial support was provided by the National 
Heart and Lung Institute, Imperial College, London, England; 
Wellcome Trust [076472/Z/05/Z]; GlaxoSmithKline, England; 
and Teijin Pharma Limited, Japan    . 
  Correspondence to:   Kazuhiro Ito, DVM, PhD, Airway Disease 
Section, National Heart and Lung Institute, Imperial College, 
Dovehouse St, London, SW3 6LY, England; e-mail: k.ito@imperial.
ac.uk 
  © 2012 American College of Chest Physicians.   This is an Open 
Access article distributed under the terms of the Creative Commons 
Attribution-Noncommercial License (http://creativecommons.
org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is 
properly cited. Information for commercial entities is available 
online  ( http://www.chestpubs.org/site/misc/reprints.xhtml).  
  DOI: 10.1378/chest.11-1536 www.chestpubs.org CHEST / 141 / 5 / MAY, 2012    1235 
performed by Welch   t   test or the Mann-Whitney   U   test. A   
P   value   ,    .05 was considered statistically signiﬁ  cant. These analyses 
were performed using Graph Pad Prism 4 Software (Graph Pad 
Prism). 
 Results 
  The Level of Nuclear HIF-1  a   Protein From 
Patients With COPD Is Lower Than That From 
Healthy Subjects Under Hypoxic Condition 
  A total of 48 subjects (21 patients with COPD 
aged 62        9 y, 12 smokers without COPD aged 
52      10 y, and 15 healthy nonsmokers aged 51      12  y) 
were recruited for this study (  Table 1    ). FEV  1   % pre-
dicted and FEV  1  /FVC of patients with COPD 
(59%     14% and 58%      10%, respectively) showed 
signiﬁ  cant airﬂ  ow limitation, whereas those of non-
smokers (97%      13%  and  80%    5%,  respectively) 
and smokers without COPD (94%        7% and 78%      4%, 
respectively) were in the normal range. The severity 
of COPD was stage II (n   5   15), stage III (n   5   5), or 
stage IV (n   5   1). Eleven out of 21 patients with COPD 
were treated with inhaled corticosteroids, 11 patients 
were treated with long-acting muscarinic antagonists, 
and eight patients were administered long-acting 
  b  -agonists. No patient was given theophylline. 
  The level of nuclear HIF-1  a   protein in PBMCs 
exposed to normal oxygen levels overnight at 37°C 
showed no signiﬁ  cant difference among the groups 
(ratio of HIF-1  a   to lamin A, 0.44        0.20 in non-
smokers, 0.30      0.23 in smokers without COPD, and 
0.46    0.40  in  patients with COPD). However, hypoxia 
(1% oxygen) signiﬁ  cantly increased HIF-1  a   expres-
sion in nuclear protein from PBMC 12-fold in non-
smokers and 24-fold in smokers, whereas the increase 
of HIF-1  a   protein in patients with COPD was only 
fourfold. The level of HIF-1  a   protein in the nuclei 
of PBMCs obtained from patients with COPD (ratio 
of HIF-1  a   to lamin A, 1.6      0.38) was signiﬁ  cantly 
lower than the levels from smokers without COPD 
 RNA  Interference 
  U937 cells and A549 cells (American Type Culture Collection) 
were grown in RPMI-1640 medium and Dulbecco modiﬁ  ed eagle 
medium, respectively, containing 10% fetal bovine serum and 
2 mM   l  -glutamine    . Short interference RNAs (siRNAs) (HDAC1, 
2, 3, 5, 7, and 8) or control siRNA (Applied Biosystems) (30 nM) 
were transfected to U937 using jetSI (Polyplus-Transfection Inc), 
and the cells were incubated for 48 h under normoxic condition, 
followed by 12 h incubation under hypoxic condition. Nuclear 
fraction was extracted and HIF-1 activities were measured using 
the TransAM kit (Active Motif). siRNA transfection to A549 cells 
was carried out with the lipofectamin RNAiMAX Transfection 
Agent (Invitrogen) and Silencer Select siRNA (Life Technologies) 
according to the manufacturer’s instructions. 
  Cigarette Smoke-Conditioned Medium 
  Commercially available tobacco (Marlboro light [Philip Morris]) 
smoke was bubbled in 10 mL phosphate buffered saline. The 
optical density (OD) of cigarette smoke-conditioned medium 
(CSM) was measured at 320 nm. CSM with an OD value of 0.5 
was used for the experiments. 
  Chromatin Immunoprecipitation Assay in VEGF Promoter 
  A549 cells were cultured in a six-well plate at a density of 
1  3  10 6   cells/well and transfected with 100 nM of siRNA of HDAC7 
and HDAC2 by the Lipofectamine RNAiMAX Transfection Agent 
(Invitrogen). Twenty-four hours later, cells were treated with 
CoCl  2   (50   m  M) and incubated for a further 24 h. Cells were then 
treated with 1% formaldehyde and 0.125 M glycine. Soluble chro-
matins were isolated by using the EZ-Zyme chromatin prep kit 
(Millipore) and immunoprecipitated with anti-HIF-1  a   anti-
body. Histone/DNA crosslinks were reversed by adding 5 N NaCl 
at 65°C for 4 h, followed by phenol/chloroform extraction 
and ethanol precipitation. PCR was performed to amplify the 
VEGF promoter using chromatin immunoprecipitation primers 
(sense 5  9 -AGACTCCACAGTGCATACGTG-3 9   and antisense 5  9 -
AGT GTGTCCCTCTGACAATG-3 9  ) as reported previously.    16    The 
PCR product was detected by StepOnePlus (Applied Biosystems). 
 Statistics 
  Results were presented as mean        SD of the mean. Multiple 
comparisons were performed by analysis of variance following 
Bonferroni multiple comparison test. When the data were not 
normally distributed, determination of variance was done by non-
parametric statistical analyses, Kruskal-Wallis analysis followed by 
Dunn post test. The comparisons between the two groups were 
  Table 1—  Patient Characteristics   
Characteristic   Nonsmokers  (n  5   15) Smokers Without COPD (n   5   12) COPD (n  5   21)
Age, y 51    12 52    10 62    9 a,b 
Sex, female (male) 6 (9) 7 (5) 8 (13)
Pack-y 0    0 24    17 60    36 c 
Smoking status, current smoker (ex-smoker) NA 12 (0) 9 (12)
FEV  1 ,  L 3.06    0.72 2.74    0.86 1.76    0.58 b,d 
FEV, % predicted 97    13 94    7 59    14 c,d 
FEV  1 /FVC,  % 80    5 78    4 58    10 c,d 
NA  5   not applicable.
  a  P   ,   .01 compared with nonsmokers.
  b  P   ,   .01 compared with smokers without COPD.
  c  P   ,   .001 compared with smokers without COPD.
  d  P   ,   .001 compared with nonsmokers.1236  Original Research
who were selected randomly. VEGF mRNA in PBMC 
in normoxic condition was 0.032      0.0079 in control 
subjects and 0.064        0.035 in patients with COPD, 
showing no statistically signiﬁ  cant difference between 
them. Hypoxia induced VEGF mRNA expression 
20-fold in healthy control subjects (0.64      0.13);  in 
contrast, the elevation was only ﬁ  vefold in patients 
with COPD (0.30      0.037)  ( Fig  2C ).  Furthermore, 
VEGF mRNA was correlated with HIF-1  a   protein 
after hypoxia exposure (r   5   0.79,  P   ,  .05)  ( Fig  2D ). 
In contrast to VEGF, IL-8 release from PBMCs 
was induced by hypoxia in both patients with COPD 
(972     286 pg/mL in normoxia and 1,607     348  pg/mL 
in hypoxia) and control subjects (392      112 pg/mL in 
normoxia and 740      178 pg/mL in hypoxia) (  Fig 2E  ), 
and the mean induction of IL-8 by hypoxia was 
2.3     0.7-fold in control subjects and 1.9     0.6-fold 
in patients with COPD, showing no statistically sig-
niﬁ  cant difference between them (  Fig 2E  ). 
 Nuclear  HIF-1 a   Protein Correlated 
With HDAC7 Protein Levels 
 The nuclear levels of HDAC7 in patients with COPD 
after exposure to hypoxia (0.37        0.11) were signiﬁ  -
cantly lower than those of nonsmokers (1.1     0.34) 
(  Fig 3A    ), although the HDAC7 protein level in nuclei 
was not different under normoxic condition between 
groups and there was no difference in HDAC7 pro-
tein level in cytoplasmic protein (data not shown). In 
addition, the mean level of HDAC7 in patients with 
(7.4     2.6) and nonsmokers (5.4      1.1) after expo-
sure to hypoxia (  Fig 1A    ). The level of HIF-1  a   pro-
tein in nuclei signiﬁ  cantly correlated with sputum 
malondialdehyde, an oxidative stress marker (r    5   0.45, 
  P   ,  .05)  ( Fig  1B ). 
 Nuclear  HIF-1 a   Protein Correlated 
With VEGF mRNA 
  VEGF is a HIF-1  a  -responsive gene. We measured 
VEGF in peripheral lung tissue obtained from a 
tissue bank linked to an established patient registry 
(e-Table 1).   15   As shown in  Figure 2A  , VEGF mRNA 
levels in the peripheral lung of patients with severe 
COPD (COPD stage III or IV, 0.16     0.037)  were 
signiﬁ  cantly lower than those of any other groups 
(nonsmokers, 0.60        0.16; smokers without COPD, 
0.52      0.14; COPD stage I or II, 0.46      0.097).  The 
levels also correlated with FEV  1   (r  5   0.57,   P   ,  .01) 
( Fig  2B ). 
 Measuring  HIF-1 a   in the lung tissue is not an 
appropriate method for comparing HIF-1  a   protein 
amounts among subjects because the samples are 
exposed to oxygen (room air) during surgical acquisi-
tion, leading to HIF-1 a  degradation. In fact, we could 
not detect HIF-1  a   protein in the peripheral lung 
tissue (data not shown). Therefore, we investigated 
the relationship between VEGF mRNA and HIF-1  a  
protein in PBMCs under ex vivo hypoxic condition. 
VEGF mRNA was measured in PBMCs obtained 
from six patients with COPD and six healthy subjects 
  Figure   1. HIF-1  a   protein in nuclei of peripheral blood mononuclear cells (PBMCs). PBMCs were 
incubated in hypoxic condition (1% oxygen, 5% CO  2  , and 94% N  2  ) for 24 h. Nuclear protein was 
extracted, and HIF-1  a   protein was detected. A, HIF-1  a   protein was normalized by lamin A. Rep-
resentative Western blot images are also shown. B, Correlation between HIF-1  a   protein in nuclei 
and sputum malondialdehyde (an oxidative stress marker). *  P   ,  .05;  **  P   ,  .01;  ***  P   ,  .001.  H  5   hypoxia; 
HIF-1  a   5   hypoxia inducible factor-1 a ; MDA  5   malondialdehyde; N  5   normoxia; NS  5   nonsmokers; 
SM  5   smokers without COPD.     www.chestpubs.org CHEST / 141 / 5 / MAY, 2012    1237 
signiﬁ  cant difference was detected between smokers 
without COPD and patients with moderate COPD. 
In addition, HDAC7 protein correlated with HIF-1  a  
protein in nuclei (r   5   0.46,  P   ,  .05)  ( Fig  3B ). 
moderate COPD was signiﬁ  cantly lower than that in 
nonsmoking healthy control subjects, and the level 
in patients with severe COPD was far lower than that 
in patients with moderate COPD (  Fig 3A  ), although no 
  Figure   2. VEGF messenger RNA (mRNA) is correlated with HIF-1  a   protein. A, VEGF mRNA in lung tissue was quantiﬁ  ed using real- 
time quantitative polymerase chain reaction (PCR). B, Correlation between FEV  1   and VEGF mRNA expression in the lung tissue. C, PBMCs 
were incubated in the hypoxic chamber (1% oxygen, 5% CO  2  , and 94% N  2  ) for 24 h, and then VEGF mRNA was quantiﬁ  ed using quan-
titative real-time PCR. D, VEGF mRNA correlated with HIF-1  a   protein expression. E, PBMCs were incubated under hypoxia 
(1% oxygen, 5% CO  2  , and 94% N  2  ) for 24 h, and then IL-8 in the supernatants was measured. VEGF mRNA values were normalized 
by GNB2L1 mRNA. HIF-1  a   values were normalized using lamin A. *  P   ,  .05;  **  P   ,  .01. GNB2L1  5   guanine nucleotide binding protein, 
  b   polypeptide 2-like 1; VEGF   5   vascular endothelial growth factor. See Figure 1 legend for expansion of other abbreviations.     
  Figure   3. Nuclear HDAC7 is correlated with HIF-1  a   protein in nuclei in PBMC. PBMCs were incu-
bated in the hypoxic chamber (1% oxygen, 5% CO  2  , and 94% N  2  ) for 24 h and nuclear protein was 
extracted. A, HDAC7 protein level in nuclei corrected to the lamin A protein expression. B, HDAC7 
protein levels correlated with HIF-1  a   protein expression. *  P   ,  .05. HDAC  5   histone deacetylase. See 
Figure 1 legend for expansion of other abbreviations.     1238  Original Research
then cells were incubated under hypoxia. HDAC7 
siRNA transfection reduced HDAC7 protein expres-
sion by 74% (e-Fig 2). Hypoxia treatment markedly 
induced HIF-1  a   nuclear translocation (  Fig 5A    ). The 
induced HIF-1  a   nuclear translocation was sig  nif-
icantly (  P   ,    .05) abolished by transfection of HDAC7 
siRNA (HIF-1  a  /lamin A/C, 0.91      0.08  with  SiNeg  ; 
0.54     0.06 with SiRNA of HDAC7) (  Fig 5A  ). 
  As shown in   Figure 5B  , the hypoxia mimic, CoCl  2  
treatment (50   m  M    , 24 h), clearly increased HIF-1  a  
binding to the VEGF promoter by chromatin immu-
noprecipitation assay analysis. However, in HDAC7 
knockdown cells, the level of HIF-1  a   binding to the 
VEGF promoter was reduced to 60% of control, but 
HDAC2 knockdown did not affect it. 
  HDAC7 Inhibition by CSM Reduced 
HIF-1  a   Protein Nuclear Translocation 
  A549 cells were treated with CSM, and HDAC7 
protein expressions in whole cell extracts were eval-
uated. Treatment with CSM significantly reduced 
HDAC7 expression (HDAC7/  b -actin,  1.96    0.21  with-
out CSM; 0.90        0.27 with CSM;   P   ,  .05)  ( Fig  5C ). 
Next, we investigated hypoxia-induced HIF-1  a   nuclear 
translocation in the presence of CSM. CSM sig-
niﬁ  cantly abolished HIF-1  a   nuclear translocation 
  HDAC Inhibition Reduced HIF-1  a   Protein Expression 
  U937 cells were treated with TSA and incu-
bated for 12 h under hypoxic condition. As shown in 
  Figure 4A    , hypoxia clearly increased the protein 
level of HIF-1  a   in nuclei. The HDAC inhibitor TSA 
inhibited HIF-1  a   expression by about 50% (  Fig 4A  ). 
In addition, TSA also inhibited HIF-1 activity in 
nuclear protein in a concentration-dependent manner 
(0.76     0.13 without TSA, 0.57      0.08 with 10 ng/mL 
TSA, and 0.39      0.05 with 100 ng/mL TSA) (  Fig 4B  ). 
siRNAs of HDAC1, 2, 3, 5, 7, and 8 were transfected,     
and we conﬁ  rmed by real-time quantitative PCR anal-
ysis a 60% to 80% reduction of mRNA level in each 
gene after 48 h of incubation. As shown in   Figure 4C  , 
HIF-1 activity under hypoxia was signiﬁ  cantly inhib-
ited by 58% with HDAC7 knockdown. However, 
HDAC1, 2, 3, 5, and 8 knockdown did not affect 
HIF-1 activity (HIF-1  a   activity, OD: control siRNA, 
0.73     0.10; HDAC1, 0.78      0.08; HDAC2, 0.64     0.05; 
HDAC3, 0.70        0.11; HDAC5, 0.94      0.15;  HDAC8, 
0.84    0.08)  ( Fig  4C ). 
  HDAC7 Knockdown Reduced HIF-1  a   Protein Nuclear 
Translocation and HIF-1  a   Binding to VEGF Promoter 
  siRNA of HDAC7 or Silencer Select negative 
control siRNA was transfected to A549 cells, and 
  Figure   4. HIF-1  a   nuclear translocation is inhibited by TSA and HDAC7 knockdown. U937 cells were 
incubated under hypoxia (1% oxygen, 5% CO  2  , and 94% N  2  ) with or without TSA. A, HIF-1  a   protein in 
nuclei was quantiﬁ  ed. B, HIF-1 activity in nuclei was quantiﬁ  ed. U937 cells were treated with siRNAs 
(HDAC1, 2, 3, 5, 7, or 8) for 48 h under normoxic condition, followed by 12-h incubation under hypoxia. 
C, HIF-1 activity in nuclei was quantiﬁ   ed.  JetSI   5  cells incubated with jetSI transfection reagent without 
siRNA; NT  5  not treated; OD  5  optical density; siRNA   5   short interference RNA; TSA   5   trichostatin A. 
See Figure 1 and 3 legends for expansion of other abbreviations.     www.chestpubs.org CHEST / 141 / 5 / MAY, 2012    1239 
12-fold and 24-fold compared with basal levels. How-
ever, the nuclear translocation of HIF-1  a   was lower 
in patients with COPD, suggesting PBMCs from 
patients with COPD respond poorly to hypoxia. This 
ﬁ  nding implies a defect in adaptation to hypoxia in 
patients with COPD due to poor activation of HIF-1  a . 
The defect of HIF-1  a   nuclear translocation was 
observed equally in both moderate and severe patients 
with COPD (HIF-1  a  /lamin A in nuclei was 1.58     0.43 
and 1.47      0.70 in moderate and severe patients with 
COPD, respectively). The mean age of the patients 
with COPD recruited in our study was higher than 
that of nonsmokers and smokers without COPD. 
However, HIF-1  a   protein levels were not correlated 
with age in patients with COPD (  r    5    2 0.011,   P   .  .05) 
(HIF-1  a  /lamin A/C, 2.20      0.06 without CSM; 1.39     
1.67 with CSM;   P   ,  .05)  ( Fig  5D ). 
 Discussion 
 HIF-1 a   is degraded rapidly under normoxic con-
dition after sampling specimens or during isolation 
of PBMCs. Therefore, it is difﬁ  cult to monitor the 
actual HIF-1  a   levels in samples taken from sub-
jects. To evaluate the HIF-1  a   response in patients 
with COPD, we exposed PBMCs collected from sub-
jects to hypoxic condition ex vivo and investigated 
the response to hypoxia. PBMCs from healthy non-
smokers and smokers responded well to hypoxia, and 
the levels of HIF-1  a   protein in nuclei increased 
  Figure   5. HDAC7 reduction by RNA interference or cigarette smoke extract affected HIF-1  a   nuclear 
translocation and VEGF promoter binding in A549 cells. siRNA of HDAC7 was transfected to 
A549, and then cells were incubated under hypoxia (0.1% oxygen, 5% CO  2  ) for 24 h. A, HIF-1  a   nuclear 
translocation was evaluated. B, HIF-1  a   binding to the VEGF promoter under treatment with CoCl  2  
(50   m  M) (mimic hypoxia) was also analyzed by chromatin immunoprecipitation (ChIP) assay. The 
ratio of the cycle threshold (Ct)     value of HIF-1  a   ChIP product to input (total cells) is shown 
(**  P   ,    .01 vs SiNeg transfection). C, A549 cells were treated with cigarette smoke-conditioned 
media (CSM) for 24 h, and then HDAC7 protein expressions in whole cell extracts were determined. 
A549 cells were treated CSM for 24 h under hypoxia or normoxia. D, HIF-1  a   protein in nuclear extracts 
was evaluated. *  P   ,  .05;  **  P   ,  .01.  CSM  5    cigarette smoke-conditioned medium; SiHD2    5   short 
interference RNA HDAC2; SiHD7    5    short interference RNA HDAC7; SiNeg    5   Silencer  Select 
negative control siRNA. See Figure 1, 3, and 4 legends for expansion of other abbreviations.   1240  Original Research
HDAC7.  26     Furthermore, it was demonstrated that 
cotransfection of HIF-1  a   and HDAC7 to human 
embryonic kidney     cells enhanced the VEGF mRNA 
in hypoxia more than overexpression of HIF-1  a   in 
the cells, whereas HDAC7 overexpression did not 
change the amount of VEGF mRNA.    26    Thus,  HDAC7 
is a prerequisite molecule to the accumulation of 
HIF-1  a   in the nucleus. Taken together, the decreased 
HIF-1  a   in nuclei of COPD under hypoxic condition 
is likely caused by the failure of the cotranslocation of 
HIF-1  a   and HDAC7 due to the decreased HDAC7 
levels in patients with COPD. 
  In our data, CSM abolished HDAC7 protein 
expression (Fig 5C) and HIF-1  a   nuclear translocation 
(Fig 5D). Clinical     data showed that HIF-1  a   in nuclei 
negatively correlated with the oxidative stress marker 
in sputum (  Fig 1B  ). The facts suggest that oxidative 
stress has an association with HIF-1  a   nuclear trans-
location, which is a condition shown in patients with 
COPD. Thus, oxidative stress seems to be an impor-
tant factor for HDAC7 depression and subsequent 
defect of HIF-1  a   nuclear translocation in COPD. 
Smoking status and pack-years did not have an asso-
ciation with HIF-1  a   in nuclei in our data. This may 
be because of the difference in endogenous antioxi-
dant levels in each patient. 
  While we were preparing this manuscript, a group 
published data showing that HIF-1  a   depression is 
observed in COPD, and HIF-1  a   correlated posi-
tively with both HDAC2 and VEGF.    27    The  authors 
speculated that HDAC2 inhibition leads to HIF-1  a  
depression. Shortly after, the authors in the same 
group published data suggesting that HDAC inhi-
bition leads to reduction of HIF-1  a   expression via 
p53 upregulation, followed by reduction of VEGF.    28   
HIF-1  a   signaling is complex. Not only expressions 
of the mRNA and proteins, but also degradation, 
nuclear translocation, and DNA binding are poten-
tially involved in the reduced HIF-1  a   in COPD. 
Here, we showed the defect of nuclear translocation 
of HIF-1  a   due to the reduction of HDAC7. In addi-
tion, we conﬁ  rmed that HIF-1  a   binding to the VEGF 
promoter region was decreased in HDAC7 knock-
down cells under the hypoxia mimic system, CoCl  2  
(  Fig 5B  ). Both mechanisms possibly exist in COPD. 
One of the mechanisms might play a role in the patho-
genesis of COPD, which is phenotype dependent. 
  The only limitation of this study was the lack of 
information on HDAC7 activity in clinical samples. 
HDACs activity is regulated by posttranslational modi-
ﬁ  cation, such as nitration and phosphorylation. We 
could not evaluate HDAC7 activity in PBMCs because 
of ethical issues because analysis of HDAC7 activity 
would require huge numbers of PBMCs. If HDAC7 
activity could be measured, additional information 
would be added to HDAC7 protein in PBMC. 
or control subjects (  r    5    2 0.084,   P   .   .05) (data not 
shown). 
  VEGF and erythropoietin genes are known to be 
upregulated by HIF-1  a   activation to adapt to hyp-
oxia by angiogenesis and stimulating erythrocyto-
sis, respectively.    1,2     In our results, hypoxia signiﬁ  cantly 
induced VEGF mRNA expression, with a concomi-
tant increase in nuclear HIF-1  a   protein in PBMCs 
from non-COPD volunteers. However, the induc-
tion level of VEGF mRNA by hypoxia was signiﬁ  -
cantly lower in PBMCs from patients with COPD 
(  Fig 2C  ). VEGF mRNA levels were also decreased 
in the peripheral lung of patients with severe COPD 
(  Fig 2A  ). This is consistent with the ﬁ  ndings of pre-
vious clinical investigations in which VEGF levels in 
the sputum of patients with severe COPD were lower 
than those of patients with other stages of COPD,    13   
despite the fact that patients with severe COPD 
usually have hypoxia, especially after exercise. The 
impaired VEGF induction response to hypoxia in 
patients with COPD is a result of the reduced HIF-1  a  
response. In contrast to VEGF, the levels of IL-8 
released from PBMC were increased by hypoxia in both 
groups, and the induction levels of the IL-8 response 
to hypoxia were not different between the groups 
(2.3      0.7-fold in control subjects and 1.9      0.6-fold  in 
patients with COPD) (  Fig 2E  ). It has been reported 
that hypoxia induces inﬂ  ammatory cytokines    17,18    via 
NF-  k  B    activation.  19     Thus, VEGF and IL-8 were induced 
by different transcription factors and this suggests that 
the hypoxia-induced HIF-1  a   response was impaired 
in the COPD but not in the NF-  k  B pathway. 
  In our data, the nuclear levels of HDAC7 in patients 
with COPD were signiﬁ  cantly lower than those in 
nonsmokers (  Fig 3A  ). Furthermore, the mean level 
of HDAC7 in patients with severe COPD after expo-
sure to hypoxia was far lower than that in patients 
with moderate COPD (  Fig 3A  ). HDAC7 is one of the 
class II HDACs    20     and has an ability to shuttle between 
the cytoplasm and nucleus, which is regulated by 
phosphorylation and dephosphorylation of the HDAC 
protein. The phosphorylation of class II HDACs is 
known to be regulated by Ca  2  1  /calmodulin-dependent 
kinase I and IV    20     and protein kinase D, which is a 
downstream effector of protein kinase C.    21-23    Muta-
tion of the phosphorylatable residues in the HDACs 
abolishes the nuclear-cytoplasmic shuttling.    24,25    I n  
this study, we showed a good correlation between 
nuclear HIF-1  a   and HDAC7 proteins in PBMC nuclei 
(  Fig 3B  ). HIF-1 activity under hypoxia was reduced 
by knockdown of HDAC7 but not by knockdown of 
HDAC1, HDAC2, HDAC3, HDAC5, or HDAC8 
(  Fig 4C  ). Furthermore, knockdown of HDAC7 abol-
ished HIF-1  a   nuclear translocation and HIF-1  a   bind-
ing to the VEGF promoter in A549 cells (  Figs 5A, 5B  ). 
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 Conclusions 
  In conclusion, a defect of HDAC7 in COPD causes 
an impaired HIF-1  a   induction in response to hypoxia 
and subsequently reduces hypoxia-induced VEGF 
expression. This HIF-1  a   defect may result in poor 
cellular adaptation to hypoxia in patients with COPD 
and may play a signiﬁ  cant role in COPD pathogenesis. 
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